Literature DB >> 20824011

Experience in Phase I Trials and an Upcoming Phase II Study with uPA Inhibitors in Metastatic Breast Cancer.

Lori J Goldstein1.   

Abstract

Entities:  

Year:  2008        PMID： 20824011      PMCID： PMC2930999          DOI： 10.1159/000151733

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN： 1661-3791            Impact factor:   2.860


× No keyword cloud information.
  26 in total

1.  Biological effects of disruption of the tissue-type plasminogen activator, urokinase-type plasminogen activator, and plasminogen activator inhibitor-1 genes in mice.

Authors:  P Carmeliet; A Bouché; C De Clercq; S Janssen; S Pollefeyt; S Wyns; R C Mulligan; D Collen
Journal:  Ann N Y Acad Sci       Date:  1995-01-17       Impact factor: 5.691

Review 2.  Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers.

Authors:  D F Hayes; R C Bast; C E Desch; H Fritsche; N E Kemeny; J M Jessup; G Y Locker; J S Macdonald; R G Mennel; L Norton; P Ravdin; S Taube; R J Winn
Journal:  J Natl Cancer Inst       Date:  1996-10-16       Impact factor: 13.506

3.  Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination.

Authors:  Nadia Harbeck; Ronald E Kates; Manfred Schmitt
Journal:  J Clin Oncol       Date:  2002-02-15       Impact factor: 44.544

Review 4.  Interference with the urokinase plasminogen activator system: a promising therapy concept for solid tumours.

Authors:  B Muehlenweg; S Sperl; V Magdolen; M Schmitt; N Harbeck
Journal:  Expert Opin Biol Ther       Date:  2001-07       Impact factor: 4.388

5.  Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse.

Authors:  N Harbeck; C Thomssen; U Berger; K Ulm; R E Kates; H Höfler; F Jänicke; H Graeff; M Schmitt
Journal:  Breast Cancer Res Treat       Date:  1999-03       Impact factor: 4.872

Review 6.  The plasminogen activation system in tumor growth, invasion, and metastasis.

Authors:  P A Andreasen; R Egelund; H H Petersen
Journal:  Cell Mol Life Sci       Date:  2000-01-20       Impact factor: 9.261

7.  Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.

Authors:  F Jänicke; L Pache; M Schmitt; K Ulm; C Thomssen; A Prechtl; H Graeff
Journal:  Cancer Res       Date:  1994-05-15       Impact factor: 12.701

8.  Prognostic value of urokinase plasminogen activator and plasminogen activator inhibitor-1 in renal cell cancer.

Authors:  R Hofmann; A Lehmer; R Hartung; C Robrecht; M Buresch; F Grothe
Journal:  J Urol       Date:  1996-03       Impact factor: 7.450

9.  Tissue-type plasminogen activator, a new prognostic marker in breast cancer.

Authors:  M J Duffy; P O'Grady; D Devaney; L O'Siorain; J J Fennelly; H R Lijnen
Journal:  Cancer Res       Date:  1988-03-01       Impact factor: 12.701

10.  Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma.

Authors:  D Cantero; H Friess; J Deflorin; A Zimmermann; M A Bründler; E Riesle; M Korc; M W Büchler
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640
View more
  8 in total

Review 1.  Urokinase plasminogen activator as an anti-metastasis target: inhibitor design principles, recent amiloride derivatives, and issues with human/mouse species selectivity.

Authors:  Nehad S El Salamouni; Benjamin J Buckley; Marie Ranson; Michael J Kelso; Haibo Yu
Journal:  Biophys Rev       Date:  2022-01-06

Review 2.  Tumor stroma as targets for cancer therapy.

Authors:  Jing Zhang; Jinsong Liu
Journal:  Pharmacol Ther       Date:  2012-10-12       Impact factor: 12.310

3.  Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells.

Authors:  Kaiji Hu; Jennifer H Law; Abbas Fotovati; Sandra E Dunn
Journal:  Breast Cancer Res       Date:  2012-02-06       Impact factor: 6.466

Review 4.  uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies.

Authors:  Michael J Duffy; Patricia M McGowan; Nadia Harbeck; Christoph Thomssen; Manfred Schmitt
Journal:  Breast Cancer Res       Date:  2014-08-22       Impact factor: 6.466

Review 5.  Therapeutic Strategies Targeting Urokinase and Its Receptor in Cancer.

Authors:  Maria Teresa Masucci; Michele Minopoli; Gioconda Di Carluccio; Maria Letizia Motti; Maria Vincenza Carriero
Journal:  Cancers (Basel)       Date:  2022-01-19       Impact factor: 6.639

Review 6.  Role of Serine Proteases at the Tumor-Stroma Interface.

Authors:  Ravichandra Tagirasa; Euna Yoo
Journal:  Front Immunol       Date:  2022-02-11       Impact factor: 7.561

Review 7.  Influence of Immune Myeloid Cells on the Extracellular Matrix During Cancer Metastasis.

Authors:  David Jiang; Su Yin Lim
Journal:  Cancer Microenviron       Date:  2016-03-09

Review 8.  Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications.

Authors:  Niaz Mahmood; Catalin Mihalcioiu; Shafaat A Rabbani
Journal:  Front Oncol       Date:  2018-02-12       Impact factor: 6.244
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.